Caroline Hopkins

Oncologists argued for and against comprehensive NGS at the point of diagnosis but agreed on the need to address quality and cost barriers first.

Through its real-world evidence registry, the firm hopes to further validate its NSCLC recurrence risk test as a tool for guiding adjuvant treatment.

The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.

A TMB-high cutoff of 10 mutations per megabase doesn't predict immunotherapy responses universally well across cancer types, according to a paper published in JAMA Oncology.

The transcription-based subtypes could differentiate which SCLC patients respond to treatments, such as immune checkpoint inhibitors and PARP inhibitors.

FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.

The findings underscore the utility of universal germline testing in young adults diagnosed with cancers that are more common in older populations.

In a retrospective study, investigators saw a survival benefit among head and neck cancer patients with high TMB treated with checkpoint inhibitors. 

The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.